Latest news with #GinkgoBioworks
Yahoo
31-07-2025
- Business
- Yahoo
Ginkgo Bioworks Announces Date of Second Quarter 2025 Results Presentation
Presentation and Q&A session scheduled for post-market on Thursday, August 7, 2025 BOSTON, July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at and a replay will be made available. To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ About Ginkgo BioworksGinkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Ginkgo Bioworks Contacts: INVESTOR CONTACT: investors@ MEDIA CONTACT: press@ View original content to download multimedia: SOURCE Ginkgo Bioworks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-07-2025
- Business
- Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest close session, Ginkgo Bioworks Holdings, Inc. (DNA) was down 6.31% at $13.96. The stock trailed the S&P 500, which registered a daily gain of 0.4%. At the same time, the Dow added 0.47%, and the tech-heavy Nasdaq gained 0.24%. Heading into today, shares of the company had gained 55.05% over the past month, outpacing the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61%. Investors will be eagerly watching for the performance of Ginkgo Bioworks Holdings, Inc. in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$1.44, reflecting a 55% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $43 million, indicating a 23.5% decrease compared to the same quarter of the previous year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$5.56 per share and a revenue of $180 million, indicating changes of +46.33% and -20.72%, respectively, from the former year. Any recent changes to analyst estimates for Ginkgo Bioworks Holdings, Inc. should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Ginkgo Bioworks Holdings, Inc. is currently sporting a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 95, positioning it in the top 39% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ginkgo Bioworks Holdings, Inc. (DNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why
Ginkgo Bioworks Holdings, Inc. (DNA) ended the recent trading session at $10.79, demonstrating a -2.53% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered a gain of 0.43%, and the technology-centric Nasdaq increased by 0.09%. The stock of company has risen by 13.19% in the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37%. The investment community will be closely monitoring the performance of Ginkgo Bioworks Holdings, Inc. in its forthcoming earnings report. The company's upcoming EPS is projected at -$1.44, signifying a 55.00% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $43 million, down 23.5% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.56 per share and revenue of $180 million, indicating changes of +46.33% and -20.72%, respectively, compared to the previous year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Ginkgo Bioworks Holdings, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Ginkgo Bioworks Holdings, Inc. currently has a Zacks Rank of #2 (Buy). The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 77, putting it in the top 32% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ginkgo Bioworks Holdings, Inc. (DNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
The Independent
28-05-2025
- Health
- The Independent
New Covid variant spreading from Asia now surges across US — what is it and where is it spreading
The new Covid variant is continuing to proliferate around the U.S. — although you might not know it by just checking federal variant-tracking dashboards. Known as NB.1.8.1, the omicron variant has been tracked in states across the country following a large surge in China. Although, right now, LP.8.1 — a descendent of JN.1 — is the nation's dominant strain. The Centers for Disease Control is in regular contact with international partners, and is aware of reported NB.1.8.1 cases in China, an agency spokesperson told The Independent. There have been too few U.S. sequences reported thus far for the variant to be included in its dashboard. But, in Asia, it's resulted in increased hospitalizations and emergency room visits. So, what should Americans know about NB.1.8.1, and how worrying is its spread? Here's what to know. What and where is NB.1.8.1? NB.1.8.1 has been designated a SARS-CoV-2 variant under monitoring, with increasing proportions globally, according to the World Health Organization. There are currently six tracked by the agency. It's spread throughout 22 countries. In the U.S., it has been traced to New York, California, Arizona, Ohio and Rhode Island, according to records from local health officials at the CDC's airport testing partner Ginkgo Bioworks. While still low in numbers, the WHO noted that there had been a significant rise in its prevalence from late March to April. What do we know about related infections? The public health risk posed by this variant is evaluated as low at the global level. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation,' the WHO said. But, while it may not be particularly severe, may infect people more easily than previous variants. There is some evidence that the variant binds more tightly to human cells. "Data indicates that NB.1.8.1 does not lead to more severe illness compared to previous variants, although it appears to have a growth advantage, suggesting it may spread more easily," Subhash Verma, a professor of microbiology and immunology at the University of Nevada, Reno School of Medicine, told CBS News this week. "In other words, it is more transmissible." Do the Covid vaccines work against NB.1.8.1? Yes, our currently-approved Covid shots are expected to remain effective against this variant and protect against severe disease. However, access to the vaccines is being limited by the Trump administration. On Tuesday, health officials said the Covid vaccine for healthy children and pregnant women had been removed from the CDC's recommended immunization schedule. The Food and Drug Administration said last week that it will continue to approve updates for seniors and Americans with underlying medication conditions. However, it will require vaccine makers to conduct major new clinical trials before approving them for wider use. Although the number of Covid-related hospitalizations and deaths has fallen considerably since the pandemic's start, experts worry about what limiting access to vaccines could do. 'Is the pharmacist going to determine if you're in a high-risk group?' Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, told The Associated Press. 'The only thing that can come of this will make vaccines less insurable and less available.' For now, people can still get the shots.
The Independent
27-05-2025
- Health
- The Independent
A new Covid variant surging in Asia is now spreading across the US. Here's where it is and what to know
The new Covid variant is continuing to proliferate around the U.S. — although you might not know it by just checking federal variant-tracking dashboards. Known as NB.1.8.1, the omicron variant has been tracked in states across the country following a large surge in China. Although, right now, LP.8.1 — a descendent of JN.1 — is the nation's dominant strain. "CDC is aware of reported cases of COVID-19 NB.1.8.1 in China and is in regular contact with international partners," a spokesperson for the Centers for Disease Control and Prevention told CBS News last week. They reportedly noted that too few U.S. sequences have been reported to be included in its dashboard. But, in Asia, it's resulted in increased hospitalizations and emergency room visits. So, what should Americans know about NB.1.8.1, and how worrying is its spread? Here's what to know. What and where is NB.1.8.1? NB.1.8.1 has been designated a SARS-CoV-2 variant under monitoring, with increasing proportions globally, according to the World Health Organization. There are currently six tracked by the agency. It's spread throughout 22 countries. In the U.S., it has been traced to New York, California, Arizona, Ohio and Rhode Island, according to records from local health officials at the CDC's airport testing partner Ginkgo Bioworks. While still low in numbers, the WHO noted that there had been a significant rise in its prevalence from late March to April. What do we know about related infections? The public health risk posed by this variant is evaluated as low at the global level. 'Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation,' the WHO said. But, while it may not be particularly severe, may infect people more easily than previous variants. There is some evidence that the variant binds more tightly to human cells. "Data indicates that NB.1.8.1 does not lead to more severe illness compared to previous variants, although it appears to have a growth advantage, suggesting it may spread more easily," Subhash Verma, a professor of microbiology and immunology at the University of Nevada, Reno School of Medicine, told CBS News this week. "In other words, it is more transmissible." Do the Covid vaccines work against NB.1.8.1? Yes, our currently-approved Covid shots are expected to remain effective against this variant and protect against severe disease. However, access to the vaccines is being limited by the Trump administration. The Food and Drug Administration said last week that it will continue to approve updates for seniors and Americans with underlying medication conditions. However, it will require vaccine makers to conduct major new clinical trials before approving them for wider use. Although the number of Covid-related hospitalizations and deaths has fallen considerably since the pandemic's start, experts worry about what limiting access to vaccines could do. 'Is the pharmacist going to determine if you're in a high-risk group?' Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, told The Associated Press. 'The only thing that can come of this will make vaccines less insurable and less available.' For now, people can still get the shots.
